Organon & Co.
Clinical trials sponsored by Organon & Co., explained in plain language.
A global healthcare company focused on women's health and biosimilars.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cream could help kids with psoriasis Results expected Oct 2026 (estimated)
- New cream could soothe eczema in babies as young as 3 months Results expected Aug 2027 (estimated)
-
New cream could help kids with psoriasis
Disease control OngoingThis study tests a cream called tapinarof for children aged 2 to 17 with plaque psoriasis, a skin condition causing red, scaly patches. The cream is applied once daily to see if it is safe and tolerable. About 58 children will take part in this open-label trial, meaning everyone …
Phase 3 • Sponsor: Organon and Co • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New cream could soothe eczema in babies as young as 3 months
Symptom relief OngoingThis study tests a cream called tapinarof on babies and toddlers aged 3 to 23 months with eczema (atopic dermatitis). The goal is to see if it can clear or nearly clear their skin rash. About 180 children will take part, and the cream is compared to a placebo (inactive cream) for…
Phase 3 • Sponsor: Organon and Co • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC